Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

E. Krop, Ian; Masuda, Norikazu; Mukohara, Toru; Takahashi, Shunji; Nakayama, Takahiro; Inoue, Kenichi; Iwata, Hiroji; Yamamoto, Yutaka; H. Álvarez, Ricardo; Toyama, Tatsuya; Takahashi, Masato; Osaki, Akihiko; Saji, Shigehira; Sagara, Yasuaki; O’Shaughnessy, Joyce; Ohwada, Shoichi; Koyama, Kumiko; Inoue, Tatsuya; Li, Li; Patel, Parul; Mostillo, Joseph; Tanaka, Yoshimi; Sternberg, David; Sellami, Dalila; Yonemori, Kan

doi:10.1200/jco.23.00882

Public

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Published in Journal of Clinical Oncology • Oct 6, 2023

Authors:

Ian E. Krop

Norikazu Masuda

Toru Mukohara

Abstract

PURPOSE: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-e...

Subject

Medicine

Breast cancer

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!